Norwood Operation — Surgical Overview

Date
October 6, 2025
URL
https://x.com/WithAScalpel/status/1975177819454914627?s=20
Categories
HLHSCardiac SurgerySingle Ventricle

Norwood Operation — Surgical Overview

image

Indication and operative intent

The Norwood operation is the first-stage palliation for neonates with hypoplastic left heart syndrome (HLHS) and related variants in which the native left heart cannot support the systemic circulation. The procedure creates a neo-aorta capable of delivering unobstructed systemic output from the right ventricle (RV), ensures unrestricted atrial mixing, and establishes a controlled source of pulmonary blood flow compatible with single-ventricle physiology. Among pulmonary blood-flow strategies, contemporary randomized and observational data show an early survival advantage with an RV–PA conduit (Sano modification) compared with a modified Blalock–Taussig shunt (mBT) [1]. Hemodynamic studies attribute this to higher diastolic pressure and more favorable coronary perfusion with RV–PA physiology [2, 3]. Center series also suggest reduced interstage mortality with RV–PA conduits, though practice is individualized to anatomy and physiology [4, 6].

Operative sequence (conceptual roadmap)

  1. Cannulation and initiation of CPB

    2. Arterial cannulation via the innominate artery and venous cannulation of the right atrium secure full cardiopulmonary bypass (CPB). This facilitates rapid transition to selective antegrade cerebral perfusion (ACP) during arch work and keeps the diminutive ascending aorta undisturbed. The patent ductus arteriosus (PDA) is ligated to prevent competitive runoff once bypass begins.

  2. Myocardial and cerebral protection; atrial septectomy

    3. After cardioplegic arrest, the atrial septal defect is widely enlarged (or a septectomy performed) to guarantee unobstructed atrial-level egress from the pulmonary venous atrium. ACP is instituted for arch reconstruction, minimizing cerebral ischemic time while the lower body is under circulatory arrest or low flow. Residual ductal tissue is excised to avoid recoil or late isthmic obstruction.

  3. Neo-aortic reconstruction (arch augmentation)

    4. The native aorta and arch are opened and extended longitudinally. A generous patch (autologous or prosthetic, center-specific) merges the proximal main pulmonary artery (MPA)/ascending aorta complex into a single, capacious neo-aorta with a smooth taper through the transverse arch and isthmus. Meticulous attention is paid to:

    • Geometric alignment of the MPA hood with the hypoplastic ascending aorta to prevent kinking and preserve laminar outflow.

    • Removal of all ductal shelf and posterior ledges at the isthmus.

    • Coronary perfusion security, ensuring the reconstructed root does not distort the coronary origins in variants with borderline ascending aorta.

  4. Source of pulmonary blood flow

    5. A right ventricle–to–pulmonary artery (RV–PA) conduit is placed from the RV free wall to the distal pulmonary artery confluence to provide controlled pulmonary perfusion. Compared with mBT shunts, RV–PA conduits have shown superior 12-month transplantation-free survival in a multicenter randomized trial (74% vs 64%) and higher diastolic arterial pressures postoperatively; however, they require ventriculotomy and are associated with more unintended interventions in the first year [1–3]. Conduit caliber (commonly 5–6 mm) is chosen to balance systemic and pulmonary flows (Qp:Qs).

  5. Wean and assessment

    6. After de-airing, wean from CPB with attention to:

    • Neo-aortic patency and low-resistance arch contour on echo/pressure assessment.

    • RV performance and tricuspid valve competence.

    • Conduit flow and branch PA anatomy, ensuring no twist or compression.

    • Hemodynamic balance (SpO₂ typically mid-70s to mid-80s on room air; lactate and SvO₂/NIRS trending favorable).

Technical considerations and pitfalls

  • Atrial septectomy must remove posterior/superior rims that can create “sling-like” or flap obstructions; any residual restriction risks pulmonary venous hypertension and low output.
  • Patch geometry across the isthmus is critical; even a minimal posterior shelf can create an early gradient. Long, generous augmentation with scrupulous hemostasis reduces early afterload and late restenosis.
  • RV–PA conduit: keep a short, straight, non-angulated course to the PA confluence; secure pledgeted RV bites to limit bleeding; avoid excessive intramyocardial depth; size to prevent both over-circulation (diastolic runoff → myocardial ischemia) and under-circulation/hypoxemia [2, 3].
  • Neoaortic valve/root: avoid commissural distortion and root malrotation that provoke regurgitation and load the single ventricle.
  • Cerebral protection: maintain ACP flows and temperature per institutional protocol; de-air the arch and head vessels meticulously before reperfusion.

Postoperative physiology and management

  • Afterload and coronary perfusion: The single RV now drives the systemic circuit; avoid hypertension that increases RV work, but maintain diastolic pressure for coronary flow. Many centers favor milrinone for lusitropy/afterload reduction and judicious vasoactive support for age-appropriate MAP.
  • Balance of Qp:Qs: Target saturations ~75–85% with normocapnia to mild hypercarbia; excessive oxygen or hyperventilation can over-dilate the pulmonary circuit and steal systemic flow.
  • Antithrombotic therapy: Protocolized antiplatelet/anticoagulation for RV–PA conduits or mBT shunts to prevent thrombosis.
  • Interstage surveillance: Nutritional support, home monitoring (weight, saturations), and early evaluation for shunt/conduit stenosis or AV-valve regurgitation are essential to reach Stage II (bidirectional Glenn) safely. Lower interstage mortality has been reported with RV–PA conduits in some series [4].

Variations, outcomes, and systems factors

  • Anatomic heterogeneity & strategy selection: Ascending aortic atresia, retrograde-dependent coronaries, arch hypoplasia into head-neck vessels, or extreme prematurity may push strategy toward mBT, RV–PA, or hybrid pathways. Strategy should be individualized to the patient’s physiology [6].
  • Evidence on shunt choice: The Single Ventricle Reconstruction (SVR) randomized trial demonstrated improved 12-month transplantation-free survival with RV–PA conduits, but also more unintended early interventions; beyond one year, survival curves converge [1]. Multiple physiologic and clinical studies corroborate higher diastolic pressure with RV–PA shunts and more stable early hemodynamics [2, 3].
  • Institutional experience: Outcomes have improved over eras with programmatic refinements, and higher institutional volume is associated with lower mortality, shorter length of stay, and lower costs after Stage I palliation [5, 8].
  • Hybrid approaches: For high-risk neonates, ductal stenting plus bilateral PA bands with delayed comprehensive Stage I is a reasonable alternative; comparative series show no consistent survival or resource-use superiority over Norwood in unselected cohorts, emphasizing patient selection and center expertise [7].

References

[1] Ohye RG, Sleeper LA, Mahony L, Newburger JW, Pearson GD, Lu M, Goldberg CS, Tabbutt S, Frommelt PC, Ghanayem NS, Laussen PC, Rhodes JF, Lewis AB, Mital S, Ravishankar C, Williams IA, Dunbar-Masterson C, Atz AM, Colan S, Minich LL, Pizarro C, Kanter KR, Jaggers J, Jacobs JP, Krawczeski CD, Pike N, McCrindle BW, Virzi L, Gaynor JW; Pediatric Heart Network Investigators. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med. 2010;362(21):1980-1992. PubMed

[2] Pizarro C, Malec E, Maher KO, Januszewska K, Gidding SS, Murdison KA, Baffa JM, Norwood WI. Right ventricle to pulmonary artery conduit improves outcome after stage I Norwood for hypoplastic left heart syndrome. Circulation. 2003;108(Suppl 1):II155-II160. PubMed

[3] Edwards L, Morris KP, Siddiqui A, Harrington D, Barron D, Brawn W. Norwood procedure for hypoplastic left heart syndrome: BT shunt or RV-PA conduit? Arch Dis Child Fetal Neonatal Ed. 2007;92(3):F210-F214. PubMed

[4] da Silva JP, da Fonseca L, Baumgratz JF, Castro RM, Franchi SM, Lianza AC, Vila JH. Hypoplastic left heart syndrome: the report of a surgical strategy and comparative results of Norwood × Norwood-Sano approach. Rev Bras Cir Cardiovasc. 2007;22(2):160-168. PubMed

[5] Azakie T, Merklinger SL, McCrindle BW, Van Arsdell GS, Lee KJ, Benson LN, Coles JG, Williams WG. Evolving strategies and improving outcomes of the modified Norwood procedure: a 10-year single-institution experience. Ann Thorac Surg. 2001;72(4):1349-1353. PubMed

[6] Bacha EA. Individualized approach in the management of patients with hypoplastic left heart syndrome (HLHS). Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2013;16(1):3-6. PubMed

[7] Brescia AA, Jureidini S, Danon S, Armbrecht E, Fiore AC, Huddleston CB. Hybrid versus Norwood procedure for hypoplastic left heart syndrome: contemporary series from a single center. J Thorac Cardiovasc Surg. 2014;147(6):1777-1782. PubMed

[8] Anderson BR, Ciarleglio AJ, Cohen DJ, Lai WW, Neidell M, Hall M, Glied SA, Bacha EA. The Norwood operation: relative effects of surgeon and institutional volumes on outcomes and resource utilization. Cardiol Young. 2016;26(4):683-692. PubMed